Use of Eylea for the Treatment of an Optic Nerve Hemangioma
18 Years
N/A
Male
Retinal Hemangioma
Trial Information
Use of Eylea for the Treatment of an Optic Nerve Hemangioma
The treatment plan will be to administer aflibercept 2.0 mg intravitreally every two to four
weeks for at least six consecutive injections. Prior to initiation of therapy and at each
study visit, a full ophthalmic examination, best-corrected visual acuity, and a complete
review of systems to monitor for any toxicity will be performed. In addition, the
investigators will perform fluorescein and indocyanine green angiography at baseline and
obtain color fundus photographs as well as spectral domain OCT images to properly document
the extent and degree of activity of the vascular tumor at baseline and at all study visits.
Inclusion Criteria:
- retinal hemangioma
- previously treated with conventional therapies, including Avastin, Lucentis, steroid,
and photodynamic therapy, with less than ideal results
Exclusion Criteria:
- ongoing reevaluation of adverse events, including inflammation, elevated intraocular
pressure, or any suspected toxicity from aflibercept
Type of Study:
Expanded Access
Study Design:
N/A
Authority:
United States: Food and Drug Administration
Study ID:
Slakter 1234
NCT ID:
NCT01714115
Start Date:
Completion Date:
Related Keywords:
- Retinal Hemangioma
- Hemangioma
- Eye Neoplasms
- Retinal Diseases
Name | Location |
|---|---|
| Vitreous Retina Macula Consultants of New York | New York, New York 10022 |
